IL210175A0 - Fn14/trail fusion proteins - Google Patents
Fn14/trail fusion proteinsInfo
- Publication number
- IL210175A0 IL210175A0 IL210175A IL21017510A IL210175A0 IL 210175 A0 IL210175 A0 IL 210175A0 IL 210175 A IL210175 A IL 210175A IL 21017510 A IL21017510 A IL 21017510A IL 210175 A0 IL210175 A0 IL 210175A0
- Authority
- IL
- Israel
- Prior art keywords
- fusion proteins
- trail fusion
- trail
- proteins
- fusion
- Prior art date
Links
- 101100046559 Mus musculus Tnfrsf12a gene Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13353208P | 2008-06-30 | 2008-06-30 | |
| PCT/US2009/003886 WO2010005519A1 (en) | 2008-06-30 | 2009-06-30 | Fn14/trail fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL210175A0 true IL210175A0 (en) | 2011-03-31 |
Family
ID=41278748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL210175A IL210175A0 (en) | 2008-06-30 | 2010-12-22 | Fn14/trail fusion proteins |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8039437B2 (enExample) |
| EP (2) | EP2297198B1 (enExample) |
| JP (1) | JP5475766B2 (enExample) |
| CN (1) | CN102137869B (enExample) |
| AU (1) | AU2009269141B2 (enExample) |
| CA (1) | CA2729351C (enExample) |
| IL (1) | IL210175A0 (enExample) |
| SG (1) | SG191698A1 (enExample) |
| WO (1) | WO2010005519A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2525822B1 (en) | 2010-01-20 | 2017-05-10 | Merck Sharp & Dohme Corp. | Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
| EP2525813B1 (en) | 2010-01-20 | 2017-01-04 | Merck Sharp & Dohme Corp. | Anti-ilt5 antibodies and ilt5-binding antibody fragments |
| PL391627A1 (pl) * | 2010-06-25 | 2012-01-02 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
| CN103153332A (zh) | 2010-09-28 | 2013-06-12 | 卡尔医疗有限公司 | 用于治疗血液恶性肿瘤的组合物和方法 |
| PL219845B1 (pl) * | 2011-01-05 | 2015-07-31 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
| CN102206281B (zh) * | 2011-03-28 | 2014-04-09 | 中国人民解放军第三军医大学第一附属医院 | 融合蛋白tetph、表达载体及其构建方法 |
| WO2012145568A1 (en) | 2011-04-21 | 2012-10-26 | Albert Einstein College Of Medicine Of Yeshiva University | Antibodies to human b7x for treatment of metastatic cancer |
| PL397167A1 (pl) * | 2011-11-28 | 2013-06-10 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Przeciwnowotworowe bialko fuzyjne |
| WO2014121093A1 (en) * | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| US10533054B2 (en) | 2013-01-31 | 2020-01-14 | Thomas Jefferson University | Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system |
| WO2014121085A1 (en) * | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Pd-l1 and pd-l2-based fusion proteins and uses thereof |
| US9797882B2 (en) | 2013-07-09 | 2017-10-24 | The Translational Genomics Research Institute | Method of screening for a compound for inhibitory activity of FN14-tweak interaction |
| US9238034B2 (en) | 2013-07-09 | 2016-01-19 | The Translational Genomics Research Institute | FN14 antagonists and therapeutic uses thereof |
| US11111284B2 (en) | 2014-08-21 | 2021-09-07 | The General Hospital Corporation | Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing |
| WO2016139668A2 (en) * | 2015-03-03 | 2016-09-09 | Kahr Medical (2005) Ltd | Dual signaling protein (dsp) fusion proteins, and methods of using thereof for treating diseases |
| IL316210A (en) | 2015-10-01 | 2024-12-01 | Heat Biologics Inc | Compounds and methods for connecting type 1 and 2 extracellular complexes as heterologous chimeric proteins |
| DK3565579T3 (da) | 2017-01-05 | 2023-09-04 | Kahr Medical Ltd | Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf |
| HRP20220230T1 (hr) | 2017-01-05 | 2022-04-29 | Kahr Medical Ltd. | Sirp1 alfa-41bbl fuzijski protein i metoda njegove upotrebe |
| US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
| WO2018127916A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A pd1-cd70 fusion protein and methods of use thereof |
| EP3585409A4 (en) | 2017-02-27 | 2020-12-02 | Shattuck Labs, Inc. | CHEMERICAL PROTEINS BASED ON CSF1R |
| JP7128195B2 (ja) | 2017-02-27 | 2022-08-30 | シャタック ラボ，インコーポレイテッド | 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法 |
| EP3585410B9 (en) | 2017-02-27 | 2023-10-04 | Shattuck Labs, Inc. | Vsig8-based chimeric proteins |
| WO2019129644A1 (en) * | 2017-12-28 | 2019-07-04 | Julius-Maximilians-Universität Würzburg | TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FcγR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCγR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA) |
| SG11202013167UA (en) | 2018-07-11 | 2021-01-28 | Kahr Medical Ltd | SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF |
| CN112543767B (zh) | 2018-07-11 | 2024-05-31 | 卡尔医学有限公司 | Pd1-4-1bbl变体融合蛋白及其使用方法 |
| US10780121B2 (en) | 2018-08-29 | 2020-09-22 | Shattuck Labs, Inc. | FLT3L-based chimeric proteins |
| JP2022541742A (ja) | 2019-07-11 | 2022-09-27 | カール メディカル リミテッド | ヘテロダイマーおよびその使用方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| IL105914A0 (en) | 1992-06-04 | 1993-10-20 | Univ California | Methods and compositions for in vivo gene therapy |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| NZ520171A (en) * | 1999-12-20 | 2005-07-29 | Immunex Corp | Tweak receptor |
| US7208151B2 (en) | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
| US7378089B2 (en) | 2001-10-02 | 2008-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Gene therapy for the prevention of autoimmune disease |
| SI1997512T1 (sl) * | 2002-04-09 | 2014-03-31 | Biogen Idec Ma Inc. | Postopki za zdravljenje stanj, povezanih s TWEAK-om |
| ATE505484T1 (de) * | 2002-10-29 | 2011-04-15 | Anaphore Inc | Trimer-proteine zur trimer-zytokine |
| AU2004259355B2 (en) * | 2003-07-24 | 2011-02-03 | Amgen Inc. | Compositions and methods relating to multimeric and oligomeric soluble fragments of the tweak receptor |
| US7285522B2 (en) | 2004-08-25 | 2007-10-23 | The Clorox Company | Bleaching with improved whitening |
-
2009
- 2009-06-30 WO PCT/US2009/003886 patent/WO2010005519A1/en not_active Ceased
- 2009-06-30 JP JP2011516335A patent/JP5475766B2/ja active Active
- 2009-06-30 CN CN200980133865.2A patent/CN102137869B/zh active Active
- 2009-06-30 AU AU2009269141A patent/AU2009269141B2/en active Active
- 2009-06-30 EP EP09788855.6A patent/EP2297198B1/en active Active
- 2009-06-30 US US12/494,680 patent/US8039437B2/en active Active
- 2009-06-30 CA CA2729351A patent/CA2729351C/en active Active
- 2009-06-30 SG SG2013049333A patent/SG191698A1/en unknown
- 2009-06-30 EP EP12001349A patent/EP2460827A1/en not_active Ceased
-
2010
- 2010-12-22 IL IL210175A patent/IL210175A0/en active IP Right Grant
-
2011
- 2011-08-11 US US13/208,091 patent/US8329657B2/en active Active
-
2012
- 2012-08-15 US US13/586,479 patent/US20130065815A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2729351C (en) | 2017-01-24 |
| US8329657B2 (en) | 2012-12-11 |
| EP2297198B1 (en) | 2014-12-17 |
| JP5475766B2 (ja) | 2014-04-16 |
| JP2011526891A (ja) | 2011-10-20 |
| US20130065815A1 (en) | 2013-03-14 |
| US20100048478A1 (en) | 2010-02-25 |
| CN102137869B (zh) | 2018-07-06 |
| AU2009269141A1 (en) | 2010-01-14 |
| EP2297198A1 (en) | 2011-03-23 |
| SG191698A1 (en) | 2013-07-31 |
| AU2009269141B2 (en) | 2013-04-04 |
| US8039437B2 (en) | 2011-10-18 |
| EP2460827A1 (en) | 2012-06-06 |
| CA2729351A1 (en) | 2010-01-14 |
| US20120028909A1 (en) | 2012-02-02 |
| WO2010005519A1 (en) | 2010-01-14 |
| CN102137869A (zh) | 2011-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL210175A0 (en) | Fn14/trail fusion proteins | |
| IL275846A (en) | ACTRIIB–FC truncated fusion proteins | |
| IL215005A0 (en) | Ox40/trail fusion proteins | |
| IL202128A0 (en) | Immunoglobulin fusion proteins | |
| IL196889A0 (en) | Albumin-insulin fusion proteins | |
| EP2413969A4 (en) | FUSION PROTEINS WITH DOG FC ELEMENTS | |
| ZA200908649B (en) | Rage fusion proteins | |
| IL204839A0 (en) | Albumin fusion proteins | |
| BRPI0918947A2 (pt) | proteína de fusão de anticorpo | |
| IL205257A0 (en) | Anti-rsv g protein antibodies | |
| IL205716A0 (en) | Formulations for taci-immunoglobulin fusion proteins | |
| SG10202100341XA (en) | Npp1 fusion proteins | |
| PL2144924T3 (pl) | Szczepionka z białkiem fuzyjnym | |
| IL236236A (en) | Antibodies to the fam26f polypeptide | |
| GB2465683B (en) | LL-37 Related Fusion Peptides | |
| EP2657337A4 (en) | FUSION PROTEIN | |
| ZA201207425B (en) | Fusion protein | |
| GB0725201D0 (en) | Peptide fusion proteins | |
| GB2465684B (en) | Biocidal fusion peptides | |
| GB0700759D0 (en) | Novel fusion protein | |
| GB0713169D0 (en) | Fusion proteins | |
| GB0709707D0 (en) | Novel fusion protein | |
| GB0919753D0 (en) | Interferon lambda fusion proteins | |
| GB0904647D0 (en) | Modified receptor fusion proteins | |
| GB0904177D0 (en) | Fusion polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |